Skip to main content
Top
Published in: Molecular Cancer 1/2005

Open Access 01-12-2005 | Research

p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells

Authors: Carmela Ciccarelli, Francesco Marampon, Arianna Scoglio, Annunziata Mauro, Cristina Giacinti, Paola De Cesaris, Bianca M Zani

Published in: Molecular Cancer | Issue 1/2005

Login to get access

Abstract

Background

p21WAF1, implicated in the cell cycle control of both normal and malignant cells, can be induced by p53-dependent and independent mechanisms. In some cells, MEKs/ERKs regulate p21WAF1 transcriptionally, while in others they also affect the post-transcriptional processes. In myogenic differentiation, p21WAF1 expression is also controlled by the myogenic transcription factor MyoD. We have previously demonstrated that the embryonal rhabdomyosarcoma cell line undergoes growth arrest and myogenic differentiation following treatments with TPA and the MEK inhibitor U0126, which respectively activate and inhibit the ERK pathway.
In this paper we attempt to clarify the mechanism of ERK-mediated and ERK-independent growth arrest and myogenic differentiation of embryonal and alveolar rhabdomyosarcoma cell lines, particularly as regards the expression of the cell cycle inhibitor p21WAF1.

Results

p21WAF1 expression and growth arrest are induced in both embryonal (RD) and alveolar (RH30) rhabdomyosarcoma cell lines following TPA or MEK/ERK inhibitor (U0126) treatments, whereas myogenic differentiation is induced in RD cells alone. Furthermore, the TPA-mediated post-transcriptional mechanism of p21WAF1-enhanced expression in RD cells is due to activation of the MEK/ERK pathway, as shown by transfections with constitutively active MEK1 or MEK2, which induces p21WAF1 expression, and with ERK1 and ERK2 siRNA, which prevents p21WAF1 expression. By contrast, U0126-mediated p21WAF1 expression is controlled transcriptionally by the p38 pathway. Similarly, myogenin and MyoD expression is induced both by U0126 and TPA and is prevented by p38 inhibition. Although MyoD and myogenin depletion by siRNA prevents U0126-mediated p21WAF1 expression, the over-expression of these two transcription factors is insufficient to induce p21WAF1. These data suggest that the transcriptional mechanism of p21WAF1 expression in RD cells is rescued when MEK/ERK inhibition relieves the functions of myogenic transcription factors. Notably, the forced expression of p21WAF1 in RD cells causes growth arrest and the reversion of anchorage-independent growth.

Conclusion

Our data provide evidence of the key role played by the MEK/ERK pathway in the growth arrest of Rhabdomyosarcoma cells. The results of this study suggest that the targeting of MEK/ERKs to rescue p21WAF1 expression and myogenic transcription factor functions leads to the reversal of the Rhabdomyosarcoma phenotype.
Appendix
Available only for authorised users
Literature
1.
go back to reference Deshpande A, Sicinski P, Hinds PW: Cyclins and cdks in development and cancer: a perspective. Oncogene. 2005, 24: 2909-2915. 10.1038/sj.onc.1208618CrossRefPubMed Deshpande A, Sicinski P, Hinds PW: Cyclins and cdks in development and cancer: a perspective. Oncogene. 2005, 24: 2909-2915. 10.1038/sj.onc.1208618CrossRefPubMed
2.
go back to reference Dash BC, El Deiry WS: Cell cycle checkpoint control mechanisms that can be disrupted in cancer. Methods Mol Biol. 2004, 280: 99-161.PubMed Dash BC, El Deiry WS: Cell cycle checkpoint control mechanisms that can be disrupted in cancer. Methods Mol Biol. 2004, 280: 99-161.PubMed
3.
go back to reference Reed SI: Control of the G1/S transition. Cancer Surv. 1997, 29: 7-23.PubMed Reed SI: Control of the G1/S transition. Cancer Surv. 1997, 29: 7-23.PubMed
4.
go back to reference Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13: 1501-1512.CrossRefPubMed Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13: 1501-1512.CrossRefPubMed
5.
go back to reference Gartel AL, Tyner AL: Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res. 1999, 246: 280-289. 10.1006/excr.1998.4319CrossRefPubMed Gartel AL, Tyner AL: Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res. 1999, 246: 280-289. 10.1006/excr.1998.4319CrossRefPubMed
6.
go back to reference Park JW, Jang MA, Lee YH, Passaniti A, Kwon TK: p53-independent elevation of p21 expression by PMA results from PKC-mediated mRNA stabilization. Biochem Biophys Res Commun. 2001, 280: 244-248. 10.1006/bbrc.2000.4105CrossRefPubMed Park JW, Jang MA, Lee YH, Passaniti A, Kwon TK: p53-independent elevation of p21 expression by PMA results from PKC-mediated mRNA stabilization. Biochem Biophys Res Commun. 2001, 280: 244-248. 10.1006/bbrc.2000.4105CrossRefPubMed
7.
go back to reference Akashi M, Osawa Y, Koeffler HP, Hachiya M: p21WAF1 expression by an activator of protein kinase C is regulated mainly at the post-transcriptional level in cells lacking p53: important role of RNA stabilization. Biochem J. 1999, 337 (Pt 3): 607-616. 10.1042/0264-6021:3370607PubMedCentralCrossRefPubMed Akashi M, Osawa Y, Koeffler HP, Hachiya M: p21WAF1 expression by an activator of protein kinase C is regulated mainly at the post-transcriptional level in cells lacking p53: important role of RNA stabilization. Biochem J. 1999, 337 (Pt 3): 607-616. 10.1042/0264-6021:3370607PubMedCentralCrossRefPubMed
8.
go back to reference Coleman ML, Marshall CJ, Olson MF: Ras promotes p21(Waf1/Cip1) protein stability via a cyclin D1-imposed block in proteasome-mediated degradation. EMBO J. 2003, 22: 2036-2046. 10.1093/emboj/cdg189PubMedCentralCrossRefPubMed Coleman ML, Marshall CJ, Olson MF: Ras promotes p21(Waf1/Cip1) protein stability via a cyclin D1-imposed block in proteasome-mediated degradation. EMBO J. 2003, 22: 2036-2046. 10.1093/emboj/cdg189PubMedCentralCrossRefPubMed
9.
go back to reference Ostrovsky O, Bengal E: The mitogen-activated protein kinase cascade promotes myoblast cell survival by stabilizing the cyclin-dependent kinase inhibitor, p21WAF1 protein. J Biol Chem. 2003, 278: 21221-21231. 10.1074/jbc.M211357200CrossRefPubMed Ostrovsky O, Bengal E: The mitogen-activated protein kinase cascade promotes myoblast cell survival by stabilizing the cyclin-dependent kinase inhibitor, p21WAF1 protein. J Biol Chem. 2003, 278: 21221-21231. 10.1074/jbc.M211357200CrossRefPubMed
10.
go back to reference Guo K, Wang J, Andres V, Smith RC, Walsh K: MyoD-induced expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal differentiation. Mol Cell Biol. 1995, 15: 3823-3829.PubMedCentralPubMed Guo K, Wang J, Andres V, Smith RC, Walsh K: MyoD-induced expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal differentiation. Mol Cell Biol. 1995, 15: 3823-3829.PubMedCentralPubMed
11.
go back to reference Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D, Lassar AB: Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science. 1995, 267: 1018-1021.CrossRefPubMed Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D, Lassar AB: Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science. 1995, 267: 1018-1021.CrossRefPubMed
12.
go back to reference Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olson EN, Harper JW, Elledge SJ: p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science. 1995, 267: 1024-1027.CrossRefPubMed Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olson EN, Harper JW, Elledge SJ: p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science. 1995, 267: 1024-1027.CrossRefPubMed
13.
go back to reference Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 1999, 18: 813-822. 10.1038/sj.onc.1202367CrossRefPubMed Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 1999, 18: 813-822. 10.1038/sj.onc.1202367CrossRefPubMed
14.
go back to reference Bennett AM, Tonks NK: Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases. Science. 1997, 278: 1288-1291. 10.1126/science.278.5341.1288CrossRefPubMed Bennett AM, Tonks NK: Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases. Science. 1997, 278: 1288-1291. 10.1126/science.278.5341.1288CrossRefPubMed
15.
go back to reference Cowley S, Paterson H, Kemp P, Marshall CJ: Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell. 1994, 77: 841-852. 10.1016/0092-8674(94)90133-3CrossRefPubMed Cowley S, Paterson H, Kemp P, Marshall CJ: Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell. 1994, 77: 841-852. 10.1016/0092-8674(94)90133-3CrossRefPubMed
16.
go back to reference Gredinger E, Gerber AN, Tamir Y, Tapscott SJ, Bengal E: Mitogen-activated protein kinase pathway is involved in the differentiation of muscle cells. J Biol Chem. 1998, 273: 10436-10444. 10.1074/jbc.273.17.10436CrossRefPubMed Gredinger E, Gerber AN, Tamir Y, Tapscott SJ, Bengal E: Mitogen-activated protein kinase pathway is involved in the differentiation of muscle cells. J Biol Chem. 1998, 273: 10436-10444. 10.1074/jbc.273.17.10436CrossRefPubMed
17.
go back to reference Tombes RM, Auer KL, Mikkelsen R, Valerie K, Wymann MP, Marshall CJ, McMahon M, Dent P: The mitogen-activated protein (MAP) kinase cascade can either stimulate or inhibit DNA synthesis in primary cultures of rat hepatocytes depending upon whether its activation is acute/phasic or chronic. Biochem J. 1998, 330 (Pt 3): 1451-1460.PubMedCentralCrossRefPubMed Tombes RM, Auer KL, Mikkelsen R, Valerie K, Wymann MP, Marshall CJ, McMahon M, Dent P: The mitogen-activated protein (MAP) kinase cascade can either stimulate or inhibit DNA synthesis in primary cultures of rat hepatocytes depending upon whether its activation is acute/phasic or chronic. Biochem J. 1998, 330 (Pt 3): 1451-1460.PubMedCentralCrossRefPubMed
18.
go back to reference Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L: ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res. 2003, 63: 1684-1695.PubMed Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L: ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res. 2003, 63: 1684-1695.PubMed
19.
go back to reference Chen G, Hitomi M, Han J, Stacey DW: The p38 pathway provides negative feedback for Ras proliferative signaling. J Biol Chem. 2000, 275: 38973-38980. 10.1074/jbc.M002856200CrossRefPubMed Chen G, Hitomi M, Han J, Stacey DW: The p38 pathway provides negative feedback for Ras proliferative signaling. J Biol Chem. 2000, 275: 38973-38980. 10.1074/jbc.M002856200CrossRefPubMed
20.
go back to reference Todd DE, Densham RM, Molton SA, Balmanno K, Newson C, Weston CR, Garner AP, Scott L, Cook SJ: ERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest. Oncogene. 2004, 23: 3284-3295. 10.1038/sj.onc.1207467CrossRefPubMed Todd DE, Densham RM, Molton SA, Balmanno K, Newson C, Weston CR, Garner AP, Scott L, Cook SJ: ERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest. Oncogene. 2004, 23: 3284-3295. 10.1038/sj.onc.1207467CrossRefPubMed
21.
go back to reference Dagher R, Helman L: Rhabdomyosarcoma: an overview. Oncologist. 1999, 4: 34-44.PubMed Dagher R, Helman L: Rhabdomyosarcoma: an overview. Oncologist. 1999, 4: 34-44.PubMed
22.
go back to reference Anderson J, Gordon A, McManus A, Shipley J, Pritchard-Jones K: Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma. Neoplasia. 1999, 1: 340-348. 10.1038/sj.neo.7900052PubMedCentralCrossRefPubMed Anderson J, Gordon A, McManus A, Shipley J, Pritchard-Jones K: Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma. Neoplasia. 1999, 1: 340-348. 10.1038/sj.neo.7900052PubMedCentralCrossRefPubMed
23.
go back to reference Tapscott SJ, Thayer MJ, Weintraub H: Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science. 1993, 259: 1450-1453.CrossRefPubMed Tapscott SJ, Thayer MJ, Weintraub H: Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science. 1993, 259: 1450-1453.CrossRefPubMed
24.
go back to reference Barr FG: Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene. 2001, 20: 5736-5746. 10.1038/sj.onc.1204599CrossRefPubMed Barr FG: Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene. 2001, 20: 5736-5746. 10.1038/sj.onc.1204599CrossRefPubMed
25.
go back to reference Keleti J, Quezado MM, Abaza MM, Raffeld M, Tsokos M: The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am J Pathol. 1996, 149: 143-151.PubMedCentralPubMed Keleti J, Quezado MM, Abaza MM, Raffeld M, Tsokos M: The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am J Pathol. 1996, 149: 143-151.PubMedCentralPubMed
26.
go back to reference Knudsen ES, Pazzagli C, Born TL, Bertolaet BL, Knudsen KE, Arden KC, Henry RR, Feramisco JR: Elevated cyclins and cyclin-dependent kinase activity in the rhabdomyosarcoma cell line RD. Cancer Res. 1998, 58: 2042-2049.PubMed Knudsen ES, Pazzagli C, Born TL, Bertolaet BL, Knudsen KE, Arden KC, Henry RR, Feramisco JR: Elevated cyclins and cyclin-dependent kinase activity in the rhabdomyosarcoma cell line RD. Cancer Res. 1998, 58: 2042-2049.PubMed
27.
go back to reference Bouche M, Senni MI, Grossi AM, Zappelli F, Polimeni M, Arnold HH, Cossu G, Molinaro M: TPA-induced differentiation of human rhabdomyosarcoma cells: expression of the myogenic regulatory factors. Exp Cell Res. 1993, 208: 209-217. 10.1006/excr.1993.1239CrossRefPubMed Bouche M, Senni MI, Grossi AM, Zappelli F, Polimeni M, Arnold HH, Cossu G, Molinaro M: TPA-induced differentiation of human rhabdomyosarcoma cells: expression of the myogenic regulatory factors. Exp Cell Res. 1993, 208: 209-217. 10.1006/excr.1993.1239CrossRefPubMed
28.
go back to reference Otten AD, Firpo EJ, Gerber AN, Brody LL, Roberts JM, Tapscott SJ: Inactivation of MyoD-mediated expression of p21 in tumor cell lines. Cell Growth Differ. 1997, 8: 1151-1160.PubMed Otten AD, Firpo EJ, Gerber AN, Brody LL, Roberts JM, Tapscott SJ: Inactivation of MyoD-mediated expression of p21 in tumor cell lines. Cell Growth Differ. 1997, 8: 1151-1160.PubMed
29.
go back to reference Sirri V, Leibovitch MP, Leibovitch SA: Muscle regulatory factor MRF4 activates differentiation in rhabdomyosarcoma RD cells through a positive-acting C-terminal protein domain. Oncogene. 2003, 22: 5658-5666. 10.1038/sj.onc.1206690CrossRefPubMed Sirri V, Leibovitch MP, Leibovitch SA: Muscle regulatory factor MRF4 activates differentiation in rhabdomyosarcoma RD cells through a positive-acting C-terminal protein domain. Oncogene. 2003, 22: 5658-5666. 10.1038/sj.onc.1206690CrossRefPubMed
30.
go back to reference Mauro A, Ciccarelli C, De Cesaris P, Scoglio A, Bouche M, Molinaro M, Aquino A, Zani BM: PKCalpha-mediated ERK, JNK and p38 activation regulates the myogenic program in human rhabdomyosarcoma cells. J Cell Sci. 2002, 115: 3587-3599. 10.1242/jcs.00037CrossRefPubMed Mauro A, Ciccarelli C, De Cesaris P, Scoglio A, Bouche M, Molinaro M, Aquino A, Zani BM: PKCalpha-mediated ERK, JNK and p38 activation regulates the myogenic program in human rhabdomyosarcoma cells. J Cell Sci. 2002, 115: 3587-3599. 10.1242/jcs.00037CrossRefPubMed
31.
go back to reference Chen PL, Scully P, Shew JY, Wang JY, Lee WH: Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell. 1989, 58: 1193-1198. 10.1016/0092-8674(89)90517-5CrossRefPubMed Chen PL, Scully P, Shew JY, Wang JY, Lee WH: Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell. 1989, 58: 1193-1198. 10.1016/0092-8674(89)90517-5CrossRefPubMed
32.
go back to reference Kim GY, Mercer SE, Ewton DZ, Yan Z, Jin K, Friedman E: The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation. J Biol Chem. 2002, 277: 29792-29802. 10.1074/jbc.M201299200CrossRefPubMed Kim GY, Mercer SE, Ewton DZ, Yan Z, Jin K, Friedman E: The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation. J Biol Chem. 2002, 277: 29792-29802. 10.1074/jbc.M201299200CrossRefPubMed
33.
go back to reference Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 1994, 372: 739-746. 10.1038/372739a0CrossRefPubMed Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 1994, 372: 739-746. 10.1038/372739a0CrossRefPubMed
34.
go back to reference Yu R, Mandlekar S, Lei W, Fahl WE, Tan TH, Kong AT: p38 mitogen-activated protein kinase negatively regulates the induction of phase II drug-metabolizing enzymes that detoxify carcinogens. J Biol Chem. 2000, 275: 2322-2327. 10.1074/jbc.275.4.2322CrossRefPubMed Yu R, Mandlekar S, Lei W, Fahl WE, Tan TH, Kong AT: p38 mitogen-activated protein kinase negatively regulates the induction of phase II drug-metabolizing enzymes that detoxify carcinogens. J Biol Chem. 2000, 275: 2322-2327. 10.1074/jbc.275.4.2322CrossRefPubMed
35.
go back to reference Zhu WG, Srinivasan K, Dai Z, Duan W, Druhan LJ, Ding H, Yee L, Villalona-Calero MA, Plass C, Otterson GA: Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter. Mol Cell Biol. 2003, 23: 4056-4065. 10.1128/MCB.23.12.4056-4065.2003PubMedCentralCrossRefPubMed Zhu WG, Srinivasan K, Dai Z, Duan W, Druhan LJ, Ding H, Yee L, Villalona-Calero MA, Plass C, Otterson GA: Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter. Mol Cell Biol. 2003, 23: 4056-4065. 10.1128/MCB.23.12.4056-4065.2003PubMedCentralCrossRefPubMed
36.
go back to reference Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, Mizutani S: Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J. 1999, 18: 1223-1234. 10.1093/emboj/18.5.1223PubMedCentralCrossRefPubMed Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, Mizutani S: Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J. 1999, 18: 1223-1234. 10.1093/emboj/18.5.1223PubMedCentralCrossRefPubMed
37.
go back to reference Chen J, Willingham T, Shuford M, Bruce D, Rushing E, Smith Y, Nisen PD: Effects of ectopic overexpression of p21(WAF1/CIP1) on aneuploidy and the malignant phenotype of human brain tumor cells. Oncogene. 1996, 13: 1395-1403.PubMed Chen J, Willingham T, Shuford M, Bruce D, Rushing E, Smith Y, Nisen PD: Effects of ectopic overexpression of p21(WAF1/CIP1) on aneuploidy and the malignant phenotype of human brain tumor cells. Oncogene. 1996, 13: 1395-1403.PubMed
38.
go back to reference Carrano AC, Eytan E, Hershko A, Pagano M: SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol. 1999, 1: 193-199. 10.1038/12013CrossRefPubMed Carrano AC, Eytan E, Hershko A, Pagano M: SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol. 1999, 1: 193-199. 10.1038/12013CrossRefPubMed
39.
go back to reference Miskimins WK, Wang G, Hawkinson M, Miskimins R: Control of cyclin-dependent kinase inhibitor p27 expression by cap-independent translation. Mol Cell Biol. 2001, 21: 4960-4967. 10.1128/MCB.21.15.4960-4967.2001PubMedCentralCrossRefPubMed Miskimins WK, Wang G, Hawkinson M, Miskimins R: Control of cyclin-dependent kinase inhibitor p27 expression by cap-independent translation. Mol Cell Biol. 2001, 21: 4960-4967. 10.1128/MCB.21.15.4960-4967.2001PubMedCentralCrossRefPubMed
40.
go back to reference Gysin S, Lee SH, Dean NM, McMahon M: Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Cancer Res. 2005, 65: 4870-4880. 10.1158/0008-5472.CAN-04-2848CrossRefPubMed Gysin S, Lee SH, Dean NM, McMahon M: Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Cancer Res. 2005, 65: 4870-4880. 10.1158/0008-5472.CAN-04-2848CrossRefPubMed
41.
go back to reference Ostrakhovitch EA, Cherian MG: Inhibition of extracellular signal regulated kinase (ERK) leads to apoptosis inducing factor (AIF) mediated apoptosis in epithelial breast cancer cells: The lack of effect of ERK in p53 mediated copper induced apoptosis. J Cell Biochem. 2005, 95: 1120-1134. 10.1002/jcb.20484CrossRefPubMed Ostrakhovitch EA, Cherian MG: Inhibition of extracellular signal regulated kinase (ERK) leads to apoptosis inducing factor (AIF) mediated apoptosis in epithelial breast cancer cells: The lack of effect of ERK in p53 mediated copper induced apoptosis. J Cell Biochem. 2005, 95: 1120-1134. 10.1002/jcb.20484CrossRefPubMed
42.
go back to reference Moretti A, Borriello A, Monno F, Criscuolo M, Rosolen A, Esposito G, Dello IR, Della RF, Iolascon A: Cell division cycle control in embryonal and alveolar rhabdomyosarcomas. Eur J Cancer. 2002, 38: 2290-2299. 10.1016/S0959-8049(02)00454-9CrossRefPubMed Moretti A, Borriello A, Monno F, Criscuolo M, Rosolen A, Esposito G, Dello IR, Della RF, Iolascon A: Cell division cycle control in embryonal and alveolar rhabdomyosarcomas. Eur J Cancer. 2002, 38: 2290-2299. 10.1016/S0959-8049(02)00454-9CrossRefPubMed
43.
go back to reference Puri PL, Wu Z, Zhang P, Wood LD, Bhakta KS, Han J, Feramisco JR, Karin M, Wang JY: Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. Genes Dev. 2000, 14: 574-584.PubMedCentralPubMed Puri PL, Wu Z, Zhang P, Wood LD, Bhakta KS, Han J, Feramisco JR, Karin M, Wang JY: Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. Genes Dev. 2000, 14: 574-584.PubMedCentralPubMed
44.
go back to reference Wu Z, Woodring PJ, Bhakta KS, Tamura K, Wen F, Feramisco JR, Karin M, Wang JY, Puri PL: p38 and extracellular signal-regulated kinases regulate the myogenic program at multiple steps. Mol Cell Biol. 2000, 20: 3951-3964. 10.1128/MCB.20.11.3951-3964.2000PubMedCentralCrossRefPubMed Wu Z, Woodring PJ, Bhakta KS, Tamura K, Wen F, Feramisco JR, Karin M, Wang JY, Puri PL: p38 and extracellular signal-regulated kinases regulate the myogenic program at multiple steps. Mol Cell Biol. 2000, 20: 3951-3964. 10.1128/MCB.20.11.3951-3964.2000PubMedCentralCrossRefPubMed
45.
go back to reference Wei Q, Paterson BM: Regulation of MyoD function in the dividing myoblast. FEBS Lett. 2001, 490: 171-178. 10.1016/S0014-5793(01)02120-2CrossRefPubMed Wei Q, Paterson BM: Regulation of MyoD function in the dividing myoblast. FEBS Lett. 2001, 490: 171-178. 10.1016/S0014-5793(01)02120-2CrossRefPubMed
46.
go back to reference Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem. 1951, 193: 265-275.PubMed Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem. 1951, 193: 265-275.PubMed
47.
go back to reference Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA: Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell. 1992, 70: 993-1006. 10.1016/0092-8674(92)90249-CCrossRefPubMed Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA: Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell. 1992, 70: 993-1006. 10.1016/0092-8674(92)90249-CCrossRefPubMed
48.
go back to reference Eustice DC, Feldman PA, Colberg-Poley AM, Buckery RM, Neubauer RH: A sensitive method for the detection of beta-galactosidase in transfected mammalian cells. Biotechniques. 1991, 11: 739-3.PubMed Eustice DC, Feldman PA, Colberg-Poley AM, Buckery RM, Neubauer RH: A sensitive method for the detection of beta-galactosidase in transfected mammalian cells. Biotechniques. 1991, 11: 739-3.PubMed
49.
go back to reference Davis RL, Weintraub H, Lassar AB: Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell. 1987, 51: 987-1000. 10.1016/0092-8674(87)90585-XCrossRefPubMed Davis RL, Weintraub H, Lassar AB: Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell. 1987, 51: 987-1000. 10.1016/0092-8674(87)90585-XCrossRefPubMed
50.
go back to reference Wright WE, Sassoon DA, Lin VK: Myogenin, a factor regulating myogenesis, has a domain homologous to MyoD. Cell. 1989, 56: 607-617. 10.1016/0092-8674(89)90583-7CrossRefPubMed Wright WE, Sassoon DA, Lin VK: Myogenin, a factor regulating myogenesis, has a domain homologous to MyoD. Cell. 1989, 56: 607-617. 10.1016/0092-8674(89)90583-7CrossRefPubMed
51.
go back to reference Mansour SJ, Candia JM, Gloor KK, Ahn NG: Constitutively active mitogen-activated protein kinase kinase 1 (MAPKK1) and MAPKK2 mediate similar transcriptional and morphological responses. Cell Growth Differ. 1996, 7: 243-250.PubMed Mansour SJ, Candia JM, Gloor KK, Ahn NG: Constitutively active mitogen-activated protein kinase kinase 1 (MAPKK1) and MAPKK2 mediate similar transcriptional and morphological responses. Cell Growth Differ. 1996, 7: 243-250.PubMed
Metadata
Title
p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells
Authors
Carmela Ciccarelli
Francesco Marampon
Arianna Scoglio
Annunziata Mauro
Cristina Giacinti
Paola De Cesaris
Bianca M Zani
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2005
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-4-41

Other articles of this Issue 1/2005

Molecular Cancer 1/2005 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine